EW · 10-Q · 2026Q3 · Full report

Liquidity and Debt Position

Edwards Lifesciences Corp · 2026-11-04 · Importance 37 · Surprise 6 · Contradicted

At September 30, 2026, cash and cash equivalents and short-term investments totaled $4.1 billion in the United States and $511.0 million outside the United States. Edwards had no borrowings under its $750.0 million unsecured revolving credit facility, which matures July 15, 2027. The company’s 4.3% fixed-rate senior notes had a carrying value of $598.8 million and mature June 15, 2028. Edwards stated that available cash, investments, operating cash flow, and credit facilities were sufficient for its current and long-term requirements.

Key facts

• Edwards Lifesciences has a $750.0 million unsecured revolving credit facility maturing July 15, 2027, with a potential $250.0 million increase and one-year maturity extension subject to lender agreement; no amounts were outstanding at September 30, 2026. source
• Edwards Lifesciences issued $600.0 million of 4.3% fixed-rate unsecured senior notes due June 15, 2028; their carrying value was $598.8 million at September 30, 2026, and none had been redeemed. source
• At September 30, 2026, Edwards Lifesciences held $4.1 billion of cash and cash equivalents and short-term investments in the United States and $511.0 million outside the United States. source
• Edwards Lifesciences believes cash and cash equivalents, short-term investments, operating cash, and credit facilities are sufficient for current and long-term working capital, capital expenditures, and other financial commitments. source

Impact estimates